Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 25, Issue 32, 2007, Pages 5078-5081

  Brundage, Michael ^a   Osoba, David ^a   Bezjak, Andrea ^a   Tu, Dongsheng ^a   Palmer, Michael ^a   Pater, Joseph ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CANCER PATIENT; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; FUNCTIONAL ASSESSMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; MEDICAL INFORMATION SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

CANADA; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; NEOPLASMS; PATIENT SATISFACTION; QUALITY INDICATORS, HEALTH CARE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 36849029718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.4645     Document Type: Conference Paper

References (26)

1. Osoba D: The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: Organization and functions. Qual Life Res 1:211-218, 1992
2. Osoba D, Bezjak A, Brundage M, et al: Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Mayo Clinic Proc (in press)
3. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
4. Osoba D, Aaronson N, Zee B, et al: Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer: The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 6:103-108, 1997
5. Osoba D: Guidelines for measuring healthrelated quality of life in clinical trials, in Staquet M, Hays RD, Fayers PM (eds): Quality of Life Assessment in Clinical Trials. Oxford, United Kingdom, Oxford University Press, 1998, pp 20-35
6. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival of patients with advanced non-small-cell lung cancer: Report of a Canadian multicentre randomized trial. J Clin Oncol 6:633-641, 1988
7. Sadura A, Pater J, Osoba D, et al: Quality-of-life assessment: Patient compliance with questionnaire completion. J Natl Cancer Inst 84:1023-1026, 1992
8. Osoba D, Zee B: Completion rates in health-related quality-of-life assessment: Approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med 17:603-612, 1998
9. Palmer M, Zee B, Bezjak A, et al: The timing of baseline quality of life in clinical trials. Qual Life Res 9:337, 2006 (abstr)
10. Osoba D, Zee B, Pater J, et al: Determinants of postchemotherapy nausea and vomiting in patients with cancer: Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-123, 1997
11. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
12. Osoba D: Interpreting the meaningfulness of changes in health-related quality of life scores: Lessons from studies in adults. Int J Cancer Suppl 12:132-137, 1999
13. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41:582-592, 2003
14. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005
15. Liu J, Tu D, Dancey J, et al: Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA 19. Breast Cancer Res Treat 100:263-271, 2006
16. Brundage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85:1138-1148, 1993
17. Paul N, Pater J, Whitehead M, et al: Methods of toxicity data collection and evaluation of the relative effectiveness of the case resort flow sheet, the patient symptom diary, and the quality of life questionnaire. Control Clin Trials 12:648, 1991 (abstr)
18. Dancey J, Zee B, Osoba D, et al: Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy - The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 6:151-158, 1997
19. Pater J, Osoba D, Zee B, et al: Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: An example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res 7:273-278, 1998
20. Bezjak A, Dixon P, Brundage M, et al: Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer. Int J Radiat Oncol Biol Phys 54:719-728, 2002
21. Bezjak A, Tu D, Seymour L, et al: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol 24:3831-3837, 2006
22. Levine MN, Pritchard KI, Bramwell VHC, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170, 2005
23. Savage C, Pater J, Tu D, et al: He said/she said: How much agreement is there on symptoms between common toxicity criteria and quality of life? Proc Am Assoc Cancer Res 21:386a, 2002 (abstr 1540)
24. Butler L, Bacon M, Carey M, et al: Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22:2461-2468, 2004
25. Brundage M, Leis A, Bezjak A, et al: Cancer patients' preferences for communicating clinical trial quality of life information: A qualitative study. Qual Life Res 12:395-404, 2003
26. Brundage M, Feldman-Stewart D, Leis A, et al: Communicating quality of life information to cancer patients: A study of six presentation formats. J Clin Oncol 23:6949-6956, 2005